As part of ongoing collaboration with Ark Surgical, ELAFY developed a thought leadership article addressing one of the most critical and evolving topics in gynecologic surgery: tissue dissemination risk in laparoscopic morcellation and the role of containment . Published in Patient Safety & Quality Healthcare (PSQH) , the article reframes containment not solely as a surgical technique, but as a broader institutional governance and risk management decision . The piece explores

ELAFY authored a feature article for Ark Surgical to be featured in FemTech World examining the hidden clinical, economic, and legal costs of uncontained morcellation — reframing tissue containment as a governance and risk management decision. Read the Featured Article here .

ELAFY supported the creation and launch of ViVac Pharma ’s website, establishing a strong digital presence aligned with the company’s innovation in the pharmaceutical and life sciences space. The project focused on developing clear positioning, refining messaging, and building a platform that communicates both the scientific foundation and strategic vision of the company to key stakeholders. The website serves as a foundation for ongoing visibility, investor communication, a

At Innovation Summit San Diego 2025, our client Ark Surgical was selected to present its vision, market opportunity, and approach to advancing safety in gynecologic surgery. The presentation was delivered by Daniela Schardinger, CEO & Founder of ELAFY Consulting, highlighting both the clinical need and the strategic opportunity in improving surgical safety within minimally invasive procedures. At the center of this work is LapBox® , Ark Surgical’s FDA-cleared tissue contai

ELAFY supported the development and launch of Ark Surgical ’s website, creating a digital platform that clearly communicates the company’s innovation in surgical safety and women’s health. The website was designed to translate complex medical technology into a compelling and accessible narrative for clinicians, investors, and strategic partners. This included positioning Ark Surgical’s LapBox® technology within the broader context of minimally invasive surgery and patient saf

ELAFY supported the strategic positioning of OCON Therapeutics within the Innovation Equity Forum (IEF) — a joint initiative of the Bill & Melinda Gates Foundation and the National Institutes of Health (NIH) — resulting in representation on the Steering Committee and participation in global discussions shaping the future of women’s health. This engagement reflects a broader effort to elevate uterine health as a critical and historically underrepresented area within global h

ELAFY supported OCON Therapeutics in securing a $10 million funding round to advance next-generation solutions in women’s health, focused on the treatment of uterine pathologies. The round was led by RH Capital, with participation from Features Capital, Astia Angels, Exerte Partners, and additional support from the Israeli Innovation Authority. ELAFY played an active role throughout the fundraising process, including: development and refinement of the investor pitch deck par

ELAFY supported the successful nomination and selection of our client OCON Therapeutics as a World Economic Forum Technology Pioneer — a global recognition awarded to companies driving innovation and impact across industries. The engagement included leading the application and submission process , translating complex technology and impact into a compelling narrative aligned with the Forum’s selection criteria. Beyond the initial recognition, ELAFY continued to support the com